Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
David P SteensmaPierre FenauxKoen Van EygenAzra RazaValeria SantiniUlrich GermingPatricia Font LopezMaria Diez-CampeloSylvain ThépotEdo VellengaMirinal S PatnaikJun Ho JangHelen VarsosJacqueline BussolariLaurie ShermanLibo SunYing WanSouria DoughertyFei HuangFaye FellerAleksandra RizoUwe PlatzbeckerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Imetelstat treatment results in a meaningful, durable TI rate across a broad range of heavily transfused patients with LR MDS who are ineligible for or relapsed/refractory to ESAs. Biomarker analyses indicated effects on the mutant malignant clone.
Keyphrases
- phase ii study
- cardiac surgery
- open label
- acute lymphoblastic leukemia
- locally advanced
- acute myeloid leukemia
- sickle cell disease
- diffuse large b cell lymphoma
- multiple myeloma
- squamous cell carcinoma
- randomized controlled trial
- hodgkin lymphoma
- risk factors
- clinical trial
- radiation therapy
- red blood cell
- combination therapy
- wild type
- replacement therapy